As of Jun 22, 2026, the Utah Medical Products stock's PE ratio is 19.57. This results from the current EPS of $3.38 and stock price of $66.14. The P/E ratio has an increase of 16% from the past four quarters average of 16.9.
The PE ratio of Utah Medical Products has averaged 22.14 over the last ten years. The current PE ratio of 19.57 is 12% below the historical average. Over the past ten years, UTMD's PE ratio was at its highest in the Jun 2018 quarter at 43.37, when the stock price was $110.15 and the EPS was $2.54. The lowest value was in the Mar 2025 quarter, when it reached 14.83 with a price of $56.04 and an EPS of $3.78.
Maximum annual increase: 62.98% in 2019
Maximum annual decrease: -52.97% in 2018
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 16.08 | 3.61% | $55.96 | $3.48 |
| 2024 | 15.52 | -15.61% | $61.47 | $3.96 |
| 2023 | 18.39 | -17.12% | $84.22 | $4.58 |
| 2022 | 22.19 | -10.13% | $100.53 | $4.53 |
| 2021 | 24.69 | -13.61% | $100 | $4.05 |
| 2020 | 28.58 | 4.88% | $84.3 | $2.95 |
| 2019 | 27.25 | 62.98% | $107.9 | $3.96 |
| 2018 | 16.72 | -52.97% | $83.08 | $4.97 |
| 2017 | 35.55 | 57.86% | $81.4 | $2.29 |
| 2016 | 22.52 | 21.53% | $72.75 | $3.23 |
| 2015 | 18.53 | -6.18% | $58.54 | $3.16 |
| 2014 | 19.75 | 5.73% | $60.05 | $3.04 |
| 2013 | 18.68 | 43.58% | $57.16 | $3.06 |
| 2012 | 13.01 | -1.74% | $36.05 | $2.77 |
| 2011 | 13.24 | -18.22% | $27 | $2.04 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 18.34 | 14.05% | $61.99 | $3.38 |
| Dec 2025 | 16.08 | -9.61% | $55.96 | $3.48 |
| Sep 2025 | 17.79 | 16.89% | $62.97 | $3.54 |
| Jun 2025 | 15.22 | 2.63% | $56.92 | $3.74 |
| Mar 2025 | 14.83 | -4.45% | $56.04 | $3.78 |
| Dec 2024 | 15.52 | -0.96% | $61.47 | $3.96 |
| Sep 2024 | 15.67 | 1.56% | $66.91 | $4.27 |
| Jun 2024 | 15.43 | -2.16% | $66.81 | $4.33 |
| Mar 2024 | 15.77 | -14.25% | $71.11 | $4.51 |
| Dec 2023 | 18.39 | -0.33% | $84.22 | $4.58 |
| Sep 2023 | 18.45 | -5.77% | $86 | $4.66 |
| Jun 2023 | 19.58 | -2.3% | $93.2 | $4.76 |
| Mar 2023 | 20.04 | -9.69% | $94.77 | $4.73 |
| Dec 2022 | 22.19 | 14.74% | $100.53 | $4.53 |
| Sep 2022 | 19.34 | -1.38% | $85.31 | $4.41 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
The current PE ratio of UTMD is greater than its 3 and 5-year historical averages, but it is below the 10-year average.
With a P/E of 19.57, UTMD is below the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 24.1, Utah Medical Products's P/E is 19% lower.
UTMD's PE ratio is lower than its peer stocks JNJ and COO, but it is greater than CNMD's. Utah Medical Products is presently trading at a lower PE ratio (19.57) than its peer group average of 32.04.
| Stock name | PE ratio | Market cap |
|---|---|---|
| CNMD CONMED Corp | 19.08 | $1.02B |
| UTMD Utah Medical Products Inc | 19.3 | $207.66M |
| JNJ Johnson & Johnson | 27.39 | $575.69B |
| MMSI Merit Medical Systems Inc | 28.61 | $4.01B |
| COO Cooper Companies Inc | 55.58 | $12.9B |
| TFX Teleflex Inc | N/A | $5.51B |
The price to earnings ratio for UTMD stock is 19.57 as of Jun 22, 2026.
As an average over the last 3 years, UTMD stock has a PE ratio of 16.76.
As an average over the last 5 years, UTMD stock has a PE ratio of 18.84.
The highest quarterly PE ratio in the last ten years has been 43.37 and it was in the Jun 2018 quarter.
UTMD's price to earnings ratio is currently 12% below its 10-year historical average.
You can calculate the PE ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Jun 22, 2026), Utah Medical Products's stock price is $66.14. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $3.38. Therefore, Utah Medical Products's P/E ratio for today is 19.57. PE RATIO(19.57) = STOCK PRICE($66.14) / TTM EPS($3.38)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.